What bothers me is that Leo puts out these Press Releases that are Obviously targeted for Retailers. If this company wants to grow it needs to stop with the nonsense small apple retailers and go for the Big Boys and I'm NOT talking about Aspire.
They are NOT the answer for CTIX, I wouldn't be surprised if they were the instigators of this false article...but we will likely never find out, they can make it difficult to track.
CTIX is coming to a crossroads in which they will eventually need at least $100 million for their expensive trials and so they will have to find a partner.
Also: Leo has been saying this uplisting B.S. for over a year now. It's put up or shut up time.
A Reverse Split is going to happen here it's just a matter of when and I know Leo doesn't want to at this time and I'm not sure that CTIX price can sustain the requisites for Nasdaq.
CTIX may have the goods but they have to convince the Big Boys and not the Retailers.
RESULTS are what will attract the big boys and so far we don't have enough information to convince them to take a chance on CTIX .... that and they are not on the Nasdaq.
Rarely do I give a thumbs up, but I completely Agree with you Growth.
Couldn't of said it better.
That is a HUGE hint "Missling is Confident enough with the Results to RS and Uplist to Nasdaq".
I am really looking forward to reading these results. If they back up what we already know that will be BIG.
I think most of us understand this, it isn't at all complicated.
If Data is good enough...the FDA could give the OK to begin large Phase III.
Right now AVXL is my favorite company and this 1:4 R/S is a very, very Smart move. Their drug could be on the market in 3 years IF everything works out (still a huge gamble) but will know much more by November, but if everything does work out AVXL can be a quick double.
MACK up 22% since I bought at 7.61, I am hoping for 50% but may settle for 35% and move profits back here since this is still low.
RPRX --- PDUFA in November also --- many have NO Clue if approved how big this one will be. A pill to stimulate pituitary to increase LH and FSH to instruct testicles to produce testosterone in secondary hypogonadism. I am in this one also since $7.50, hoping it will hit $12 at least. In 2013 it was $30 so I don't think $12 is a huge ask.
Not sure how long CTIX will stay this low. Any positive news could likely double this to $3.50 range, I bet Leo hates instructing Aspire to buy this low, but I guarantee you this will have a very nice run and I (for selfish reasons) hope this sticks around below 1.50 for two weeks and then it can fly away.
$20 per share will Still be under a $Billion Market Cap.
Next year this stock may sky rocket.
If this is truly a blockbuster drug $1 Billion a year this could easily validate a $10 Billion market cap or $200 per share post split.
This one could go down in story book history about how it has taken off since March.
You have to remember that 99.999% of AD drugs simply did NOT work and that is why AVXL received NO Attention and to add they were on the OTC.
Things are about to get really exciting.
is doing things the Right way.
Look do you believe that he would have a 1:4 R/S only to have the price right back down to $1.85 level?
Absolutely NOT. He knows that this drug is showing improvements that NO other drug in history has EVER displayed.
The effective split date to Nas is November 9th, just two days POST Conference results.
If the news was negative then the price would immediately Retract below Nasdaq requisites and it would make NO sense whatsoever.
This means that the news will be good, the stock price will Climb higher and now we can have Institutional Ownership.
This is FOR the Big Boys so they can actively participate.
The market cap is under $250 million and remember Biogen's market cap skied up to add $10 BILLION in market cap when they believed they had something, but as we found out AVXL is MUCH, MUCH BETTER!
I believe there will be great opportunities for Newbies and us longs to add at nice levels post split as many don't understand and will give their shares up to Smart Money Traders.
AVXL will be Officially on the Map. No longer perceived as a pink sheet.
The 40 Million shares that will be outstanding will be gobbled up by long smart money and they won't let it go.
$4 post split will be $1 pre-split and I can't wait to gobble up some Cheap shares if people start to dump.
I am holding my shares and hoping to more than triple my position after this split if the price dips.
Good Luck Longs!
would NEVER in a lifetime present bad news after having this 1 for 4 Reverse Split. The news will be positive, he wants to insure that the Big Boys can participate after the announcement.
BUT Now we will be vulnerable to some manipulation, but I reiterate there is NO WAY that the "Late Breaking News" on November 7th is Bad, NO WAY!
My advice is to Buy on All the dips.
Remember AVXLD until the actual upgrade takes place to Nas.
I am liking this CEO more and more each day...he sure isn't a dummy like most small cap bio CEO's, this guy is making Brilliant moves here.
The price could present some Bargain prices if there is a panic sell because people don't understand what's going on.
Until we receive some Really Positive NEWS there may be Volatility. The chart doesn't look pretty and is in a major down trend.
This should go back up because Aspire had to buy over $2 and when they want this to run, it will RUN.
I wish I was smart enough to invest some money in a stock like this when I was in college!
When to buy? Buy on any pullback because we will have news at the end of year and I expect a nice run.
This literally could have a Billion Dollar market cap by the first of the new year, so do the math on the potential stock price.
Biogen's market cap went up by $10 BILLION Dollars on what they believed they had for AD...now it very much appears that AVXL has a much better chance and it won't be long until other pharma's recognize this and that in itself will just create more value.
the BEST in Class drug for CIC and will immediately take market away from Forest and IRWD's Linaclotide.
Linzess isn't doing bad even though it is not the right choice for IBS-C...when SGYP is approved it will be Goodbye Linzess, because it is simply MUCH BETTER, plain and simple.
As far as a buyout, I do believe there are big pharma taking a look at this and I believe there is Enough Data to date to surmise multiple phase III results.
This will double in the near future and shorts will be toasted.
Long Term this is Mega Blockbuster.
If you would of bought at .48 cents when I first "Chirped" and said this was a long termer, you would be in GREAT Shape!
My favorite follower: BuffyGirlHen!
Misleading Folks: Sounds like you do your research from these Boards and rely on others to aid in making your personal trades.
That my friend is called a Buff---oon!
Maybe you should buy some AVXL now because it just may reward you Big Time!
This post indicates that they believe the data thus far has not been released on enough patients...which the poster is correct, but the data for the few patients is very compelling...especially when patients, family and physicians all are in concert about continuing treatment. That is very positive and why you see this stock gaining the mass attention.
It seems that the big data will be at the end of the year with bonus data in between, so in my opinion this will only continue to gain traction.
It's not just about AD anymore, these compounds may treat multiple CNS diseases.
It will be very interesting to see the stock price one year from now.
break 1.70 to avoid a double top here.
Could have a big move if the Bio's continue to climb. Right now all indicators appear to be very strong for a nice move up.
ANY positive news right now would likely produce a powerful move upward.
12 to 24 months: That all depends on if this is approved...not intending to be smart #$%$ here.
Chances of Approval: So far there have been two that have gone for approval and both of those turned down by FDA.
I like LPCN...but it does leave a couple "questions" with possible peak testosterone levels as it may come down to the food studies. The more "fat" in food the Higher the peak and I believe they should of performed this study with higher fat levels.
The technology of bypassing liver seems to be best in class (safety is good).
The main concern may be Peak Levels.
I think they have the best product that will be in front of FDA for approval and if approved in 24 months from now this could be $80 to $120 and that's no joke as this will Quickly take market share away from the Shots and Gels.
The main concern is the FDA right now and that decision is a long ways away which is why you will see a lot of posts that have nothing to do with LPCN.
I believe the Run-UP could be significant in anticipation of approval.
I like both LPCN and RPRX. RPRX deals with aiding the pituitary gland and possibly hypothalamus to produce LH and FSH which is very low in Secondary Hypogonadism. I like this way the best because you are receiving testosterone from your testicles rather than just external testosterone.
This is a new approach but if this is approved doctors will likely prescribe for the label, but would likely leave plenty of room for LPCN also --- Plenty of room.
So for both of these companies it is now in the hands of the FDA.
Bottomline: If LPCN is approved, I believe LPCN will have an instant $1.5 Billion value or around $60---$65 a share and be a true buyout candidate.